Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii | Zendy

Jiaqi Cheng | Zendy; Jun Yan | Zendy; Zeferino Reyna | Zendy; Matt Slarve | Zendy; Peggy Lu | Zendy; Brad Spellberg | Zendy; Brian Luna | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii

Author(s) -

Jiaqi Cheng,

Jun Yan,

Zeferino Reyna,

Matt Slarve,

Peggy Lu,

Brad Spellberg,

Brian Luna

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02204-20

Subject(s) - rifabutin , colistin , acinetobacter baumannii , microbiology and biotechnology , medicine , antibiotics , drug resistance , carbapenem , biology , bacteria , genetics , pseudomonas aeruginosa , clarithromycin

Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research